<p>Sera Prognostics（納斯達克代碼：SERA - 獲取免費報告）於週三發佈了季度財報。該公司報告季度每股收益為（$0.16），超出市場普遍預期的（$0.17）$0.01，FiscalAI 報道。Sera Prognostics 的淨利潤率為負 34,343.16%，股本回報率為負 41.69%。該季度的營業收入為 0.01 百萬美元，而分析師預計為 0.03 百萬美元。</p>
<p>獲取 <strong>Sera Prognostics</strong> 的提醒：</p>
<h2>Sera Prognostics 價格表現</h2>
<p>週三，納斯達克 SERA 股價下跌 $0.10，報 $1.91。該股票的交易量為 217,068 股，而其平均交易量為 59,219 股。該公司的 50 日移動平均價格為 $2.70，200 日移動平均價格為 $3.03。該股票的市值為 $7373 萬，市盈率為 -2.48，貝塔係數為 1.01。Sera Prognostics 的 52 周低點為 $1.37，52 周高點為 $4.20。</p>
<h2>華爾街分析師預測增長</h2>
<p>SERA 最近成為多份研究報告的主題。傑富瑞金融集團在 12 月 15 日的研究報告中將 Sera Prognostics 的股票評級上調至 “強力買入”。Weiss Ratings 在 12 月 29 日的研究報告中重申了對 Sera Prognostics 股票的 “賣出（d-）” 評級。一位分析師給予該股票 “強力買入” 評級，另一位則給予 “賣出” 評級。根據 MarketBeat 的數據，該股票目前的平均評級為 “適度買入”，平均目標價為 $5.00。</p>
<p><strong>查看我們關於 Sera Prognostics 的最新報告</strong></p>
<h2>Sera Prognostics 的內部買賣情況</h2>
<p>在其他新聞中，首席執行官 Zhenya Lindgardt 於 3 月 10 日星期二出售了 22,639 股該公司的股票。股票以平均價格 $1.90 出售，總價值為 $43,014.10。出售完成後，首席執行官持有 741,287 股公司股票，價值 $1,408,445.30。此次交易代表其持股比例下降 2.96%。該交易已在向證券交易委員會提交的文件中披露，文件可通過此鏈接獲取。在過去的九十天裏，內部人士出售了價值 $115,794 的 57,133 股公司股票。公司內部人士持有 15.80% 的股份。</p>
<h2>機構投資者對 Sera Prognostics 的看法</h2>
<p>機構投資者最近增加或減少了對該公司的持股。Lido Advisors LLC 在第三季度以 $68,000 的估值收購了 Sera Prognostics 的新頭寸。Cetera Investment Advisers 在第四季度以約 $74,000 的估值收購了 Sera Prognostics 的新股份。Two Sigma Investments LP 在第三季度以約 $97,000 的估值購買了 Sera Prognostics 的新頭寸。Qube Research &amp; Technologies Ltd 在第二季度以約 $92,000 的估值收購了 Sera Prognostics 的新頭寸。最後，巴克萊 PLC 在第四季度將其在 Sera Prognostics 的持股增加了 267.4%。巴克萊 PLC 目前持有 36,722 股公司股票，價值 $108,000，此前在該期間又購買了 26,726 股。機構投資者和對沖基金持有公司 54.64% 的股份。</p>
<h2>Sera Prognostics 公司簡介</h2>
<p>（獲取免費報告）</p>
<p>Sera Prognostics, Inc 是一家精準醫療公司，專注於通過蛋白質組學檢測改善妊娠結果。該公司的旗艦產品 PreTRM™ 測試是一種基於血液的檢測，旨在通過測量母體血清中的特定蛋白生物標誌物來評估女性早產的風險。通過識別有自發早產高風險的患者，Sera Prognostics 旨在實現更早的干預和量身定製的護理計劃，從而減少與早產相關的新生兒併發症的發生率。</p>
<p>自 2014 年成立以來，Sera Prognostics 在 2020 年首次公開募股後，與美國各地的臨牀研究網絡和產科護理提供者密切合作，以驗證其 PreTRM 測試的臨牀表現。</p>
<h2>推薦故事</h2>
<ul>
<li>我們更看好的五隻股票，而不是 Sera Prognostics</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9U0VSQQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9U0VSQQ"/></p>
<p><em>此即時新聞提醒由敍述科學技術和來自 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 $1,000 在 Sera Prognostics 嗎？</h2>
<p>在考慮 Sera Prognostics 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，以便在更廣泛的市場注意到之前進行購買……而 Sera Prognostics 並不在名單上。</p>
<p>雖然 Sera Prognostics 目前在分析師中獲得 “適度買入” 評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>查看這五隻股票</p>

SERA

標普生物技術 3 倍做多 - Direxion

動態生物技術與基因組 ETF - Invesco

紐交所高增長板生物技術指數 ETF - First Trust

醫藥突破 ETF - ALPS

標普生物技術 ETF - SPDR

2 倍做多納斯達克生物技術 ETF - ProShares

生物科技 ETF - VanEck Vectors

納斯達克生物科技指數 ETF - iShares Nasdaq

<p>Sera Prognostics (NASDAQ:SERA) 報告季度每股收益為（$0.16），超出預期的（$0.17）$0.01。該公司產生的收入為$0.01 百萬，低於預期的$0.03 百萬。Sera Prognostics 的股本回報率為負 41.69%，淨利潤率為負 34,343.16%。股票交易價格下跌至$1.91，市值為$73.73 百萬。分析師的評級不一，包含一個強烈買入和一個賣出。機構投資者持有 54.64% 的股份，首席執行官 Zhenya Lindgardt 最近出售了價值$43,014.10 的股份</p>

<p>Sera Prognostics (NASDAQ:SERA - Get Free Report) posted its quarterly earnings results on Wednesday. The company reported ($0.16) EPS for the quarter, beating the consensus estimate of ($0.17) by $0.01, FiscalAI reports. Sera Prognostics had a negative net margin of 34,343.16% and a negative return on equity of 41.69%. The business had revenue of $0.01 million during the quarter, compared to analyst estimates of $0.03 million.</p>
<div class="lb-trans"><p>Sera Prognostics（納斯達克代碼：SERA - 獲取免費報告）於週三發佈了季度財報。該公司報告季度每股收益為（$0.16），超出市場普遍預期的（$0.17）$0.01，FiscalAI 報道。Sera Prognostics 的淨利潤率為負 34,343.16%，股本回報率為負 41.69%。該季度的營業收入為 0.01 百萬美元，而分析師預計為 0.03 百萬美元。</p>
</div><p>Get <strong>Sera Prognostics</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Sera Prognostics</strong> 的提醒：</p>
</div><h2>Sera Prognostics Price Performance</h2>
<div class="lb-trans"><h2>Sera Prognostics 價格表現</h2>
</div><p>NASDAQ SERA traded down $0.10 on Wednesday, hitting $1.91. The stock had a trading volume of 217,068 shares, compared to its average volume of 59,219. The business's fifty day moving average price is $2.70 and its 200 day moving average price is $3.03. The stock has a market cap of $73.73 million, a price-to-earnings ratio of -2.48 and a beta of 1.01. Sera Prognostics has a 52-week low of $1.37 and a 52-week high of $4.20.</p>
<div class="lb-trans"><p>週三，納斯達克 SERA 股價下跌 $0.10，報 $1.91。該股票的交易量為 217,068 股，而其平均交易量為 59,219 股。該公司的 50 日移動平均價格為 $2.70，200 日移動平均價格為 $3.03。該股票的市值為 $7373 萬，市盈率為 -2.48，貝塔係數為 1.01。Sera Prognostics 的 52 周低點為 $1.37，52 周高點為 $4.20。</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>華爾街分析師預測增長</h2>
</div><p>SERA has been the subject of a number of recent research reports. Jefferies Financial Group raised shares of Sera Prognostics to a &#34;strong-buy&#34; rating in a research note on Monday, December 15th. Weiss Ratings reaffirmed a &#34;sell (d-)&#34; rating on shares of Sera Prognostics in a research report on Monday, December 29th. One analyst has rated the stock with a Strong Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of &#34;Moderate Buy&#34; and an average price target of $5.00.</p>
<div class="lb-trans"><p>SERA 最近成為多份研究報告的主題。傑富瑞金融集團在 12 月 15 日的研究報告中將 Sera Prognostics 的股票評級上調至 “強力買入”。Weiss Ratings 在 12 月 29 日的研究報告中重申了對 Sera Prognostics 股票的 “賣出（d-）” 評級。一位分析師給予該股票 “強力買入” 評級，另一位則給予 “賣出” 評級。根據 MarketBeat 的數據，該股票目前的平均評級為 “適度買入”，平均目標價為 $5.00。</p>
</div><p><strong>Check Out Our Latest Report on Sera Prognostics</strong></p>
<div class="lb-trans"><p><strong>查看我們關於 Sera Prognostics 的最新報告</strong></p>
</div><h2>Insider Buying and Selling at Sera Prognostics</h2>
<div class="lb-trans"><h2>Sera Prognostics 的內部買賣情況</h2>
</div><p>In other news, CEO Zhenya Lindgardt sold 22,639 shares of the firm's stock in a transaction on Tuesday, March 10th. The stock was sold at an average price of $1.90, for a total value of $43,014.10. Following the completion of the sale, the chief executive officer owned 741,287 shares of the company's stock, valued at $1,408,445.30. This trade represents a 2.96% decrease in their position. The transaction was disclosed in a document filed with the Securities &amp; Exchange Commission, which is available through this hyperlink. Over the last ninety days, insiders sold 57,133 shares of company stock valued at $115,794. 15.80% of the stock is owned by company insiders.</p>
<div class="lb-trans"><p>在其他新聞中，首席執行官 Zhenya Lindgardt 於 3 月 10 日星期二出售了 22,639 股該公司的股票。股票以平均價格 $1.90 出售，總價值為 $43,014.10。出售完成後，首席執行官持有 741,287 股公司股票，價值 $1,408,445.30。此次交易代表其持股比例下降 2.96%。該交易已在向證券交易委員會提交的文件中披露，文件可通過此鏈接獲取。在過去的九十天裏，內部人士出售了價值 $115,794 的 57,133 股公司股票。公司內部人士持有 15.80% 的股份。</p>
</div><h2>Institutional Investors Weigh In On Sera Prognostics</h2>
<div class="lb-trans"><h2>機構投資者對 Sera Prognostics 的看法</h2>
</div><p>Institutional investors have recently added to or reduced their stakes in the business. Lido Advisors LLC acquired a new position in Sera Prognostics during the third quarter valued at $68,000. Cetera Investment Advisers acquired a new stake in Sera Prognostics during the 4th quarter worth about $74,000. Two Sigma Investments LP purchased a new position in shares of Sera Prognostics during the 3rd quarter valued at about $97,000. Qube Research &amp; Technologies Ltd acquired a new position in shares of Sera Prognostics in the 2nd quarter valued at about $92,000. Finally, Barclays PLC lifted its holdings in shares of Sera Prognostics by 267.4% in the 4th quarter. Barclays PLC now owns 36,722 shares of the company's stock valued at $108,000 after buying an additional 26,726 shares during the period. Institutional investors and hedge funds own 54.64% of the company's stock.</p>
<div class="lb-trans"><p>機構投資者最近增加或減少了對該公司的持股。Lido Advisors LLC 在第三季度以 $68,000 的估值收購了 Sera Prognostics 的新頭寸。Cetera Investment Advisers 在第四季度以約 $74,000 的估值收購了 Sera Prognostics 的新股份。Two Sigma Investments LP 在第三季度以約 $97,000 的估值購買了 Sera Prognostics 的新頭寸。Qube Research &amp; Technologies Ltd 在第二季度以約 $92,000 的估值收購了 Sera Prognostics 的新頭寸。最後，巴克萊 PLC 在第四季度將其在 Sera Prognostics 的持股增加了 267.4%。巴克萊 PLC 目前持有 36,722 股公司股票，價值 $108,000，此前在該期間又購買了 26,726 股。機構投資者和對沖基金持有公司 54.64% 的股份。</p>
</div><h2>Sera Prognostics Company Profile</h2>
<div class="lb-trans"><h2>Sera Prognostics 公司簡介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Sera Prognostics, Inc is a precision medicine company focused on improving pregnancy outcomes through proteomic testing. The company's flagship product, the PreTRM™ test, is a blood-based assay designed to assess a woman's risk of delivering prematurely by measuring specific protein biomarkers in maternal serum. By identifying patients at elevated risk for spontaneous preterm birth, Sera Prognostics aims to enable earlier interventions and tailored care plans that can reduce the incidence of neonatal complications associated with early delivery.</p>
<div class="lb-trans"><p>Sera Prognostics, Inc 是一家精準醫療公司，專注於通過蛋白質組學檢測改善妊娠結果。該公司的旗艦產品 PreTRM™ 測試是一種基於血液的檢測，旨在通過測量母體血清中的特定蛋白生物標誌物來評估女性早產的風險。通過識別有自發早產高風險的患者，Sera Prognostics 旨在實現更早的干預和量身定製的護理計劃，從而減少與早產相關的新生兒併發症的發生率。</p>
</div><p>Since its founding in 2014 and subsequent initial public offering in 2020, Sera Prognostics has worked closely with clinical research networks and obstetric care providers across the United States to validate the clinical performance of its PreTRM test.</p>
<div class="lb-trans"><p>自 2014 年成立以來，Sera Prognostics 在 2020 年首次公開募股後，與美國各地的臨牀研究網絡和產科護理提供者密切合作，以驗證其 PreTRM 測試的臨牀表現。</p>
</div><h2>Recommended Stories</h2>
<div class="lb-trans"><h2>推薦故事</h2>
</div><ul>
<li>Five stocks we like better than Sera Prognostics</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票，而不是 Sera Prognostics</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9U0VSQQ" alt="" original-src="https://www.marketbeat.com/scripts/EarningsChart.ashx?Prefix=NASDAQ&amp;Symbol=SERA"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和來自 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Sera Prognostics Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 $1,000 在 Sera Prognostics 嗎？</h2>
</div><p>Before you consider Sera Prognostics, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 Sera Prognostics 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sera Prognostics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，以便在更廣泛的市場注意到之前進行購買……而 Sera Prognostics 並不在名單上。</p>
</div><p>While Sera Prognostics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Sera Prognostics 目前在分析師中獲得 “適度買入” 評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看這五隻股票</p>
</div>

Sera Prognostics (NASDAQ:SERA) Releases Quarterly Earnings Results, Beats Expectations By $0.01 EPS

Market Beat

Sera Prognostics

Sera Prognostics（納斯達克代碼：SERA）公佈季度財報，每股收益超出預期 0.01 美元